Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 152.50
Bid: 150.00
Ask: 155.00
Change: -5.00 (-3.17%)
Spread: 5.00 (3.333%)
Open: 157.50
High: 157.50
Low: 152.50
Prev. Close: 157.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

25 Sep 2013 07:00

RNS Number : 8123O
Revolymer PLC
25 September 2013
 



25 September 2013

Revolymer plc

Unaudited Interim Results for the 6 month period to 30 June 2013

 

Revolymer plc (AIM: REVO) ("Revolymer", the "Company" or the "Group"), the British polymer company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the high value fast moving consumer goods ("FMCG") and other industrial markets, today announces its unaudited interim results for the 6 month period to 30 June 2013.

 

Business Highlights

· Cash, cash equivalents and short term investments of £19.7m at the period end (2012: £1.4m) (31 December 2012: £21.9m) - reflecting the significant resources on hand to advance Revolymer's development portfolio and fund the execution of its strategy of commercialising its technology by partnership with larger industry players

· Portfolio progress - of the Company's portfolio of over 20 projects, a small number are in the later stages of partnered development and, if successful, associated commercialisation deals are expected to be closed in the next twelve months

· Developments in the prioritised Consumer Specialties business area:-

o Household Products - continued progress in parallel of a number of partnered projects developing Revolymer's proprietary formulations of cleaning actives for stabilisation in both liquid and solid formats

o Personal Care - ongoing partnered development of a number of personal care product prototypes incorporating the Group's moisture management technology

o Coatings & Adhesives - advances in partnered projects applying Revolymer moisture management technology to non-laundry household products and sealants used in the construction industry

· Nicotine gum - a significant contract win to supply a Canadian retailer for an initial period of two years covering a number of stock-keeping units in different flavours and formats, including a new 'handy pack' (announced post period end on 22 July 2013).

 

Financial Highlights

· Revenue for the period of £22k (2012: £135k) - the largest constituent being sales of nicotine gum in Canada. The reduction in total revenue compared to 2012 reflects the previously announced decision to discontinue sales of removable and degradable confectionery gum in the US from the start of 2013

· Gross loss for the period of £254k (2012: £242k) - after charging a non-cash stock write down of £262k (2012: £305k). Unlike the first 6 months of 2012 when the write down pertained to time expiring US confectionery gum, in 2013 the charge relates to a non-cash write down of raw material polymer stocks due to uncertainty over the timing of its consumption in the business. Gross profit for the period before the non-cash stock write down was £8k (2012: £63k)

· Other operating income for the period of £166k (2012: £88k) - reflecting increased receipts from potential commercial partners in the Consumer Specialties business area

· Loss for the period of £2.9 million (2012: loss £4.0 million) - after making non-cash charges in respect of (i) share based payments to employees (i.e. option grants) of £95k (2012: £1.5 million); and (ii) £218k primarily relating to the impairment of manufacturing fixed assets used in the production of polymer stock.

 

Dr Roger Pettman CEO of Revolymer said: "The Company remains committed to its previously stated strategy of focusing on developing and then licensing itsportfolio of projects, funded by the significant net proceeds of our IPO last year. We continue to make progress in a number of parallel partnered projects in high value markets and believe that this will lead to the successful commercialisation of our polymer technologies in due course."

 

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Simon Rigby / David Dible / Ginny Pulbrook

 

Cautionary statement

Information in this announcement is based upon unaudited management accounts and, in addition, certain statements made are forward looking. Such statements are based on current expectations at the date of this announcement and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results referred to in these forward looking statements. The Company and its directors undertake no obligation to update or revise forward looking statements to reflect any change in expectations or any change in events, conditions or circumstances.

 

Chief Executive's Statement

 

Business Overview

Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing products within the FMCG and other industrial markets. Revolymer aims to generate growing high quality revenue streams by licensing its unique technologies to manufacturers and marketers within these markets. Potential applications for the business's technology are in the household products, personal care and coatings & adhesives product areas ("Consumer Specialties"), and in medicated chewing gum (including nicotine gum) and confectionery chewing gum ("Chewing Gum").

 

Update

 

Portfolio

The ongoing progress during the period of more than 20 product projects (which cover a range of different applications but focused in the strategically important and high value Consumer Specialties business area) continues to provide the Group with a number of licence opportunities. This strategy reduces the Company's dependency on a single product success, thereby serving to mitigate some of the inherent challenges associated with the development of appropriate commercialisation partnerships. Engagement with potential licensees in parallel also can contribute to Revolymer's leverage in licensing negotiations. Within our portfolio there are now a small number of projects in the later stages of partnered development in respect of which, if successful, commercialisation deals are expected to be closed within the next twelve months.

 

Consumer Specialties

The Group has made continued progress in parallel in a number of partnered projects developing Revolymer's proprietary formulations of household cleaning actives for stabilisation in both liquid and solid formats. These projects rely on Revolymer's know-how, expertise and other intellectual property (including patents and patent applications) in polymer-based encapsulation and spheronisation.

 

During the reporting period, Revolymer also worked on ongoing partnered development of a number of personal care product prototypes incorporating the Group's moisture management technology. The Personal Care business areas include skin care and cosmetics, hair and nail care, as well as dental care.

 

Advances have also been made during the period in partnered projects applying Revolymer's moisture management technology to non-laundry household products and sealants used in the construction industry.

 

Chewing Gum - Post period end development

As announced on 22 July 2013, Revolymer has been awarded a contract to supply its nicotine gum to a Canadian retailer. The deal is for an initial period of two years and the product is scheduled to be on sale in Q4 2013. Under the terms of the deal, Revolymer will supply a number of stock-keeping units of nicotine gum in different flavours and formats, including a new 'handy pack'.

 

Financial Overview

Cash, cash equivalents and short term investments on hand at the period end were £19.7m (2012: £1.4m) (31 December 2012: £21.9m), reflecting a net cash outflow from the business for the six month period of £2.2m (2012: £1.7m). Whilst in the comparable period in 2012 the Group was conserving cash ahead of its listing and initial public offering ("IPO") on AIM in July 2012, in 2013 it has continued to exercise close control over expenditure with a view to delivering on its stated business plan during the window funded by the net proceeds of the IPO.

 

Revenue for the period totalled £22k (2012: £135k). The reduction in revenue compared to 2012 reflects the discontinuation of direct sales of removable and degradable confectionery gum in the US from the start of 2013, as previously announced. The largest component of revenue in 2013 was sales of nicotine gum in Canada, although sales of polymer for incorporation into gumbase (as a manufacturing intermediary for subsequent use by the business) are also included.

 

Gross loss for the period was £254k (2012: £242k) after a non-cash provision of £262k (2012: £305k) included in cost of sales. The provision relates primarily to the non-cash write down of Rev7 polymer stocks on hand, reflecting the uncertainty around the rate of future consumption of Rev7 polymer within the business. Whilst management are working towards executing a number of partnership deals applying the Group's moisture management technology (which includes the Rev7 polymer) that would consume such polymer stocks in due course, it is not possible to predict the timing of these transactions accurately. In contrast, the provision in the comparable period related to stocks of US confectionery chewing gum approaching expiry. Excluding this provision, gross profit in the period was £8k (2012: £63k).

 

Other operating income for the period was £166k (2012: £88k), comprising receipts from potential commercial partners in the Consumer Specialties business area, with the increased level of income reflecting the advanced status of a number of our external collaborations.

 

The loss for the period was £2.9m (2012: £4.0m loss) after charging administrative expenses of £2.9m (2012: £3.9m). Administrative expenses include a non-cash charge under IFRS2 relating to share options granted during the period of £95k (2012: £1.5 million). Before this non-cash charge administrative expenses were £2.8m (2012: £2.4m). The loss is also after non-cash charges relating to Revolymer's contract manufacture arrangements for Rev7 polymer. Consistent with the write down in Rev7 polymer stocks described above, it is also necessary to provide for an impairment of £161k to the carrying value of manufacturing fixed assets and a provision for potential liabilities of £57k under the third party manufacturing contract in respect of minimum volume requirements (2012: nil). Before both the share based payment and manufacture-related non-cash charges, administrative expenses were £2.6m (2012: £2.4m). Finally the loss for the period is after crediting finance income of £105k (2012: nil) relating to the cash, cash equivalents and short term deposits on hand following Revolymer's IPO.

 

Outlook

Management continues to focus on progressing a large portfolio of partnered development projects covering applications of the Group's polymer technologies across a broad range of business areas primarily in the strategically important Consumer Specialties business area, and looks forward to further announcements of transactions in due course.

 

Condensed Consolidated Income Statement and Statement of Comprehensive Income

For the six months ended 30 June 2013

Unaudited

Unaudited

Audited

6 Months to 30 June

2013

6 Months to 30 June

2012

Year to 31 December

2012

Notes

£000

£000

£000

Revenue

6

22

135

176

Cost of sales

5

(276)

(377)

(782)

Gross profit/(loss)

(254)

(242)

(606)

Other operating income

166

88

340

Administrative expenses

5

(2,871)

(3,852)

(9,858)

Operating loss

5

(2,959)

(4,006)

(10,124)

Finance income

105

-

50

Loss for the period before tax

(2,854)

(4,006)

(10,074)

Taxation expense

-

-

-

Loss for the period

(2,854)

(4,006)

(10,074)

 

 

 

Basic and Diluted loss per share

8

5.3p

14.3p

25.2p

 

 

All amounts relate to continuing activities.

 

There were no recognised income and expenses other than the loss for the year and the previous year. Accordingly a separate condensed consolidated statement of comprehensive income has not been presented.

 

 

Condensed consolidated statement of financial position

As at 30 June 2013

Audited

Unaudited

As at 30 June

2013

 

Unaudited

As at 30 June

2012

 

As at 31 December

2012

Notes

£000

£000

£000

Non-current assets

Property, plant and equipment

7

391

613

545

391

613

545

Current assets

Inventories

-

491

255

Trade and other receivables

328

429

300

Investments

4

17,000

-

17,000

Cash and cash equivalents

4

2,659

1,380

4,899

19,987

2,300

22,454

Total assets

20,378

2,913

22,999

Non-current liabilities

Finance lease obligations

(204)

(102)

(102)

(204)

(102)

(102)

Current liabilities

Trade and other payables

(1,825)

(1,389)

(1,805)

(2,029)

(1,389)

(1,907)

Net assets

18,349

1,422

21,092

Equity

Equity share capital

538

-

538

Equity share premium

22,923

17,906

22,908

Own shares reserve

(7)

-

(8)

Merger reserve

17,626

-

17,626

Foreign currency retranslation reserve

-

2

-

Share based payment reserve

5,902

3,227

5,807

Retained earnings

(28,633)

(19,713)

(25,779)

Total equity

18,349

1,422

21,092

 

 

Condensed consolidated statement of changes in equity

For the six months ended 30 June 2013

Equity share capital

Equity share premium

Foreign currency retranslation reserve

Own shares reserve

Merger reserve

Share based payment reserve

Retained earnings

Total

£000

£000

£000

£000

£000

£000

£000

£000

At 1 January 2012 (audited)

-

17,906

2

-

-

1,748

(15,707)

3,949

Retained loss for the period

-

-

-

-

-

-

(4,006)

(4,006)

Share options

-

-

-

-

-

1,479

-

1,479

At 30 June 2012 (unaudited)

-

17,906

2

-

-

3,227

(19,713)

1,422

Retained loss for the period

-

-

-

-

-

-

(6,068)

(6,068)

Reclassification

-

-

(2)

-

-

-

2

-

Shares issued to EBT

8

-

-

(8)

-

-

-

-

Combination of Revolymer (U.K.) Limited

280

(17,906)

-

-

17,626

-

-

-

Issue of equity share capital

250

24,750

-

-

-

-

-

25,000

Costs of issuing shares

-

(1,842)

(1,842)

Share options

-

-

-

-

-

2,580

-

2,580

At 31 December 2012 (audited)

538

22,908

-

(8)

17,626

5,807

(25,779)

21,092

Retained loss for the period

-

-

-

-

-

-

(2,854)

(2,854)

Issue of shares *

-

15

-

1

-

-

-

16

Share options

-

-

-

-

-

95

-

95

At 30 June 2013 (unaudited)

538

22,923

-

(7)

17,626

5,902

(28,633)

18,349

 

* During the period vested options over 60,000 1p ordinary shares were exercised, generating proceeds of £15,700. In addition, exercises of vested options over 40,500 one pence ordinary shares at an exercise price of nil were satisfied by the holdings in the EBT.

 

 

Interim condensed consolidated statement of cash flows

For the six months ended 30 June 2013

Unaudited

Unaudited

Audited

6 Months to 30 June

 2013

6 Months to 30 June

 2012

Year to 31 December

2012

£000

£000

£000

Cash flows from operating activities

Operating loss

(2,959)

(4,006)

(10,124)

Adjustments for:

Depreciation of property, plant and equipment

283

131

269

Share option charge

95

1,479

4,059

Decrease/(increase) in inventories

255

279

515

Decrease in receivables

50

12

188

Increase in payables

122

407

823

 

 

 

Net cash outflow from operating activities

(2,154)

(1,698)

(4,270)

Cash flows from investing activities

Interest received

27

-

3

Funds placed on term deposits

(10,000)

-

(17,000)

Funds returned from term deposits

10,000

-

-

Purchase of property, plant and equipment

(129)

(5)

(75)

Net cash outflow from investing activities

(102)

(5)

(17,072)

Cash received from issue of shares

16

-

25,000

Transaction costs of issuing shares

-

-

(1,842)

Net cash inflow from financing activities

16

-

23,158

Net (outflow)/inflow in cash and cash equivalents

(2,240)

(1,703)

1,816

Cash and cash equivalents at beginning of the period

4,899

3,083

3,083

Cash and cash equivalents at end of the period

2,659

1,380

4,899

 

Notes to the interim condensed consolidated financial statements

1. Corporate information

These interim condensed financial statements of Revolymer plc (the "Company") for the six months ended 30 June 2013 were authorised for issue in accordance with a resolution of the directors (the "Directors") on 23 September 2013. Revolymer plc is a public limited company incorporated in the United Kingdom whose shares began trading on the AIM Market of the London Stock Exchange on 10 July 2012.

2. Basis of preparation - IFRS

 

These interim condensed consolidated financial statements for the six months ended 30 June 2013 have been prepared in accordance with IAS 34 Interim Financial Reporting; and using the recognition and measurement principles of International Accounting Standards, International Financial Reporting Standards and Interpretations adopted for use in the European Union (collectively 'Adopted IFRS').The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements and should be read in connection with the latest annual report. The same accounting policies, presentation and methods of computation are followed in this condensed set of financial statements as applied in the Group's latest annual audited financial statements for the year ended 31 December 2012.

The interim condensed consolidated financial statements are presented in sterling and all values are rounded to the nearest thousand (£'000), except when otherwise indicated, and are prepared on the historical cost basis.

Going Concern

The financial statements have been prepared on a going concern basis which the Directors believe continues to be appropriate. The Company meets its day to day working capital requirements through existing cash resources and short term investments which, at 30 June 2013, amounted to £19.7 million (31 December 2012: £21.9 million, 30 June 2012: £1.4 million).

3. Risks and uncertainties

 

Revolymer plc's approach to managing the risks and uncertainties of its business was reported in the Annual Report and Financial Statements for the year ended 31 December 2012 and is unchanged.

 

4. Cash, cash equivalents and investments

Unaudited

Unaudited

Audited

Six Months to 30 June

2013

Six Months to 30 June

2012

 Year to 31 December

2012

£000

£000

£000

Term deposits maturing within one year

17,000

-

17,000

Cash at bank and in hand

2,659

1,380

4,899

19,659

1,380

21,899

 

 

5. Operating Loss

For the purpose of comparison with prior periods the table below shows the calculation of operating loss with the stock write downs and share based payment charges separately identified.

 

Unaudited

Unaudited

Audited

6 Months to 30 June

2013

6 Months to 30 June

2012

Year to 31 December

2012

£000

£000

£000

Revenue

22

135

176

Cost of sales before stock write down

(14)

(72)

(249)

Gross profit/(loss) before stock write down

8

63

(73)

Stock write down

(262)

(305)

(533)

Gross loss

(254)

(242)

(606)

Other operating income

166

88

340

Administrative expenses before share-based payment charge

(2,776)

(2,373)

(5,799)

Share-based payments charge

(95)

(1,479)

(4,059)

Operating loss

(2,959)

(4,006)

(10,124)

 

6. Segmental analysis

Revenue by business segment:

For management purposes the Company is organised into business units based on its products and services, and has two reportable segments.

 

The Consumer Specialties segment designs, develops and formulates novel polymers for improving the performance of existing consumer products in various market segments including personal care, household products and coatings and adhesives.

 

The Chewing Gum segment includes the development and commercialisation of medicated chewing gum (which includes nicotine gum) and confectionery chewing gum.

 

6. Segmental analysis - continued

 

Six months ended 30 June 2013

 

Chewing Gum

Consumer Specialties

Unaudited

6 months to 30 June 2013

£000

£000

£000

Revenue

22

-

22

Geographical information

Canada

12

-

12

Italy

10

-

10

22

-

22

 

 

Six months ended 30 June 2012

 

Chewing Gum

Consumer Specialties

Unaudited

6 months to 30 June 2012

£000

£000

£000

Revenue

135

-

135

Geographical information

Italy

1

-

1

Canada

16

-

16

United States

118

-

118

135

-

135

 

 

Year ended 31 December 2012

 

Chewing Gum

Consumer Specialties

Audited

Year to 31 December 2012

£000

£000

£000

Revenue

176

-

176

Geographical information

United Kingdom

1

-

1

Eire

4

-

4

Canada

16

-

16

Italy

2

-

2

United States

153

-

153

176

-

176

 

Net assets of the Company are attributable solely to the UK.

7. Property, plant and equipment

 

During the six months ended 30 June 2013, the Company acquired plant and equipment with a cost of £129k (30 June 2012: £5k) (year ended 31 December 2012: £75k).

8. Loss per share

Unaudited

Unaudited

Audited

6 Months to 30 June

2013

6 Months to 30 June

2012

Year to 31 December

2012

£000

£000

£000

Weighted average number of ordinary shares for the

 purposes of basic and diluted loss per share ('000)

53,830

28,015

39,909

9. Share based payments

During the six months to 30 June 2013, 1,033,273 share options were granted under the Revolymer LTIP 2012 scheme as either unapproved options or approved options under the HMRC approved EMI scheme. The fair value of equity-settled share options granted is estimated as at the date of grant using a Black-Scholes model, taking into account the terms and conditions upon which the options were granted using the following assumptions.

Unapproved

Options

EMI

Options

Number of options granted

692,957

340,316

Exercise price

£nil

£0.475-£0.71

Expected volatility

50%

50%

Risk free rate

0.5%

0.5%

Expected dividend yield

0%

0%

 

The EMI options have a vesting period of three years with no performance criteria. The vesting period of the Unapproved LTIP awards is also three years but they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 30 day period ending on the third anniversary of grant is £1.25. Between weighted average ordinary share prices of £1.25 and £1.50, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £1.25 the grants are not exercisable and lapse in full.

The charge for share based payments for the period to 30 June 2013 was £95k (30 June 2012: £1,479k) (31 December 2012: £4,059k).

 

10. Related party transactions

Transactions between the Company and its subsidiaries, which are related parties, have been eliminated on consolidation.

Remuneration of key management personnel

The remuneration of the Directors, who are considered to be the key management personnel of the Company, is set out below in aggregate for each of the categories specified in IAS 24 'Related Party Disclosures'.

Unaudited

Unaudited

Audited

Six Months to 30 June

2013

Six Months to 30 June

2012

Year to 31 December

2012

£000

£000

£000

Wages and salaries

376

179

742

Directors' fees invoiced by third parties

20

74

128

Post-employment benefits

19

-

35

Equity settled share based payment expense

63

364

2,643

478

617

3,548

Other related party transactions

The Company was invoiced during the period by IP2IPO Limited, a company of which Mr M Townend is a director, for consultancy fees and other expenses in respect of Mr Townend's services. Mr M Townend is a related party by virtue of his position as a director of the Company.

The Company was invoiced during the period by Grand Cru Consulting Limited, a company of which Mr J Keenan is a director, for consultancy fees and other expenses in respect of Mr Keenan's services. Mr J Keenan is a related party by virtue of his position as a director of the Company.

Receipts from related parties

Payments to related parties

Amounts due to related parties

Amounts due from related parties

£000

£000

£000

£000

6 months to 30 June 2013

IP2IPO Services Limited

-

7

4

-

Grand Cru Consulting Limited

-

13

-

-

 

6 months to 30 June 2012

ColloidScience Limited

-

27

9

-

IP2IPO Services Limited

-

8

11

-

Swarraton Partners Limited

-

7

7

-

Naxos Limited

-

8

8

-

Grand Cru Consulting Limited

-

26

5

-

 

Year to 31 December 2012

ColloidScience Limited

-

48

-

-

IP2IPO Services Limited

-

19

4

-

Swarraton Partners Limited

-

6

-

-

Naxos Limited

-

15

-

-

Grand Cru Consulting Limited

-

51

4

-

 

All related party transactions were made on terms equivalent to those that prevail in arm's length transactions. There have been no write-offs of related party balances during the year and there are no provisions against any related party balances. The terms and conditions of related party transactions are the same as those for other debtors and creditors.

11. Contingent liability

As previously announced, the Company received notification from Fertin Pharma A/S and Gumlink A/S of the commencement of patent infringement proceedings against it in connection with the sale of its nicotine gum in Canada. Following professional advice, management considers there are strong grounds for rebutting this action and therefore continues to defend vigorously the Company's position. However, there can be no guarantee that a liability will not result from this matter, although at this time it cannot be quantified.

12. Events after the reporting period

 

On 22 July 2013, the Company announced that it has been awarded a contract to supply its nicotine gum to a Canadian retailer. The deal is for an initial period of two years. Revolymer has begun manufacture, and the product is scheduled to be on the shelves in Q4 2013. Under the terms of the deal Revolymer will supply a number of stock-keeping units of nicotine gum in different flavours and formats, including a new 'handy pack'.

 

 

CORPORATE INFORMATION

 

Revolymer Plc (registered number 08024489)

 

Directors:

John Michael Joseph Keenan (Non-executive Chairman)

Dr Roger Bruce Pettman (Chief Executive Officer)

Robin James Scott Cridland (Chief Financial Officer)

Dr Bryan Crawford Dobson (Independent Non-executive Director)

Robert Milton Frost (Non-executive Director)

Julian Spenser Heslop (Independent Non-executive Director)

Michael Charles Nettleton Townend (Non-executive Director)

 

Company Secretary:

Robin James Scott Cridland

 

Registered Office:

1 Newtech Square

Zone 2, Deeside Industrial Park

Deeside

Flintshire CH5 2NT

 

Nominated Adviser and Broker:

Panmure Gordon (UK) Limited

One New Change

London

EC4M 9AF

 

Auditors:

Ernst &Young LLP

100 Barbirolli Square

Manchester M2 3EY

 

Solicitors:

Field Fisher Waterhouse LLP

35 Vine Street

London EC3N 2AA

 

Patent Agents:

D Young & Co LLP

120 Holborn

London EC1N 2DY

 

Registrar:

Capita Registrars Limited

The Registry

34 Beckenham Road

Beckenham

Kent BR3 4TU

 

Company website: www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR PGURWBUPWGRC
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.